Abstracts Archive - Page 170 of 2607 - ACR Meeting Abstracts

Abstract Number: 0950 • ACR Convergence 2025
Ep300-Catalyzed Rad50 Lactylation Compromises Genomic Stability and Drives CD4+T cells Cell Senescence in SLE
mingyang zhang¹, huanzi dai², cun lan³ and mingyang sun³, ¹Daping Hospital, Army Medical University, chongqing, Chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic), ³Daping Hospital, Army Medical University, chongqing, China (People's Republic)
Background/Purpose: Senescent CD4+ T cells are increasingly implicated in systemic lupus erythematosus (SLE) pathogenesis. While metabolic reprogramming in lupus T cells enhances glycolysis and lactate…
Abstract Number: 0662 • ACR Convergence 2025
Efficacy Across Baseline Characteristic Subgroups in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib: Results From SLEek, a Phase 2 Randomized
Marta Mosca¹, Karen H. Costenbader², Amit Saxena³, Michelle Petri⁴, Andrea Rubbert-Roth⁵, Karim Masri⁶, Christopher Saffore⁷, Ling Cheng⁸ and Joan Merrill⁹, ¹University of Pisa, Pisa, Pisa, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁴Johns Hopkins University School of Medicine, Timonium, MD, ⁵Division of Rheumatology and Immunology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., waukegan, IL, ⁸AbbVie, North, IL, ⁹Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK
Background/Purpose: Clinical and immunological manifestations of systemic lupus erythematosus (SLE) vary widely across patients, complicating diagnosis and treatment (1,2). Upadacitinib (UPA), an oral selective JAK…
Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Isabella Hartel¹, Jay Patel¹, Justin Levinson¹, Sancia Ferguson², Carmen Campbell¹, Amannda Weber³, Shelby Gomez⁴, David Gazeley⁵, Ali Duarte-Garcia⁶, Jennifer Barton⁷ and Shivani Garg⁸, ¹University of Wisconsin, School of Medicine and Public Health, Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, Madison, WI, ³University of Wisconsin (UW), UW Health, Madison, WI, ⁴University of Wisconsin, School of Pharmacy, Madison, WI, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Mayo Clinic, Rochester, MN, ⁷VA Portland Health Care System/OHSU, Portland, OR, ⁸University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…
Abstract Number: 1028 • ACR Convergence 2025
Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
Ning Meng¹, Scott Zeger², John Miller¹, Uzma Haque³, Thomas Grader-Beck⁴, Laura Hummers⁵, Clifton Bingham¹, Ami Shah⁵, Ana-Maria Orbai⁶ and Ji Soo Kim⁷, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins Biostatistics, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD, ⁴Johns Hopkins, Reisterstown, MD, ⁵Johns Hopkins Rheumatology, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins, Baltimore, MD
Background/Purpose: The clinical Disease Activity in Psoriatic Arthritis (cDAPSA) score is widely used to assess PsA disease activity and its trajectory. cDAPSA sums four measures:…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 1072 • ACR Convergence 2025
Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review
Manuel Carpio Tumba¹, Raisa Lomanto Silva², Lily Sung³, Laura C. Pedraza-Arévalo⁴, Sneha Gupta⁵, Jeenah Gwak⁶, Aida Mohamadi⁷, Diana Louden⁸, Rachael Stovall⁸, Namrata Singh⁹, Didem Saygin¹⁰, Sarah Lieber¹¹, Jiha Lee¹² and Sebastian E Sattui¹³, ¹University of Pittsburgh, Pittsburgh, PA, ²Massachusetts General Hospital, Boston, MA, ³Stanford University Hospital & Clinics, Hayward, CA, ⁴St. Barnabas Hospital, New York, NY, ⁵University of Pittsburgh Medical Center McKeesport, McKeesport, PA, ⁶Stanford University, Palo Alto, CA, ⁷Tehran University of Medical Sciences, Tehran, Iran, ⁸University of Washington, Seattle, WA, ⁹University of Washington, Bellevue, WA, ¹⁰Rush University Medical Center, Chicago, IL, ¹¹Hospital for Special Surgery, New York, NY, ¹²University of Michigan, Ann Arbor, MI, ¹³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: A growing number of older adults are living with autoimmune rheumatic diseases (AIRDs) as the global population is aging. And yet, they remain underrepresented…
Abstract Number: 0519 • ACR Convergence 2025
A Multi-criterion Feature Integration Framework for Accurate Diagnosis of Primary Sjögren’s Syndrome Using Routine Laboratory Tests: A Multicentre, Retrospective Cohort study
Shu Liu¹, Guanhao Wu¹, Mengge Pan¹, Qi Sun², Jingchen Gao¹, Xianming Long³, Chaogui Tang⁴, Xinran Yuan¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China (People's Republic), ²Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong, China, Nantong, China (People's Republic), ³The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China (People's Republic), ⁴The Affiliated Huaian First People’s Hospital of Nanjing Medical University, Huai’an First People’s Hospital, Nanjing Medical University, Huaian, China (People's Republic)
Background/Purpose: Primary Sjögren's syndrome (pSS) is a prevalent systemic autoimmune disorder. However, the early and accurate diagnosis of pSS remains challenging due to its non-specific…
Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Bich Na Choi¹, Claudia Pedroza², Brian Skaug³, Maureen Mayes⁴ and Shervin Assassi⁵, ¹UTHealth Houston Institute for Clinical Research & Learning Health Care, Houston, TX, ²UTHealth Houston Institute for Clinical Research & Learning Health Care, Texas, TX, ³UTHealth Houston Division of Rheumatology, Houston, TX, ⁴UT Health Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
Abstract Number: 0033 • ACR Convergence 2025
Development and Internal Validation of Two Human Leukocyte Antigen Genetic Risk Scores for Predicting Rheumatoid Arthritis Progression and Anti-Citrullinated Protein Antibody-Positivity
Lauren Vanderlinden¹, Jun Inamo², Jennifer Seifert³, V. Michael Holers⁴, Joel Guthridge⁵, Kevin Deane⁶ and Fan Zhang⁷, ¹University of Colorado Anschutz Medical Campus, Monument, CO, ²University of Colorado School of Medicine, Aurora, CO, ³University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁴University of Colorado, Denver, CO, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁷The University of Colorado, Aurora, CO
Background/Purpose: Human leukocyte antigen (HLA) class II genes play a central role in antigen presentation and immune modulation. The shared epitope (SE) region within HLA-DRB1…
Abstract Number: 1082 • ACR Convergence 2025
Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Rashi Vora¹, Samiha Karim², Dulaney Wilson³, Jasvinder Singh⁴, Gary Gilkeson¹, Jim Oates¹ and Diane Kamen⁵, ¹Medical University of South Carolina, Charleston, SC, ²Emory University, Atlanta, GA, ³Medical University of South Carolina, Charleston, ⁴Baylor College of Medicine, Houston, TX, ⁵Medical University of South Carolina, Johns Island, SC
Background/Purpose: Minority patients with systemic lupus erythematosus (SLE) experience a higher disease burden and encounter more barriers to care than White patients, resulting in worse…
Abstract Number: 0684 • ACR Convergence 2025
Translation to Spanish and Linguistic Validation of the Assessment of Systemic Sclerosis-associated Raynaud’s Phenomenon (ASRAP)
Antonia Valenzuela¹, Adriana Miguel Alvarez², Patricia E. Carreira³, Alejandra Babini⁴, Diana Rocío Gil Calderón⁵, John Pauling⁶ and Tatiana Rodriguez-Reyna², ¹Pontificia Universidad Catolica de Chile, Santiago, Chile, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Hospital Universitario ¹² de Octubre, Madrid, Spain, ⁴Hospital Italiano, Córdoba, Argentina, ⁵Hospital Universitario Mayor MEDERI, Universidad del Rosario, Artmedica SAS, Bogotá, Colombia, ⁶North Bristol NHS Trust, Bristol, United Kingdom
Background/Purpose: Systemic sclerosis-associated Raynaud’s phenomenon (SSc-RP) significantly impacts patients’ quality of life, yet validated tools to assess this condition in Spanish-speaking populations are lacking. The…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 1085 • ACR Convergence 2025
Bridging the Gap: The Use of Patient Joint Self-Assessment in RA Treatment Response Evaluation
Sri Lakshmi Sathiyaseelan¹, Sandeep Kansurkar², Kavita Krishna³ and Varsha Bhatt⁴, ¹Bharati Vidyapeeth medical college and hospital, chennai, Tamil Nadu, India, ²Bharti vidyapeeth (DTU) Medical College, Pune, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ⁴Department of Clinical Immunology and Rheumatology, Bharati Vidyapeeth (Deemed To Be) University Medical College,Pune, Pune, Maharashtra, India
Background/Purpose: Rheumatoid arthritis presents with multiple joint pains and it is traditionally, examined by the clinicians. The utility of patient self‐joint counts has become an…
Abstract Number: 0504 • ACR Convergence 2025
Spatial profiling of gene signatures in synovial tissue informs treatment strategy for Rheumatoid Arthritis
Vincent Wong¹, Katie Lowe², Annabelle Small³, Christopher Altmann³, Susanna Proudman⁴, Malcolm Smith², Wittaya Suwakulsiri⁵, Ranjeny Thomas⁵, Chung Hoow Kok⁶ and Mihir Wechalekar⁷, ¹College of Medicine and Public Health, Bedford Park, South Australia, Australia, ²Flinders University, Adelaide, South Australia, Australia, ³Flinders University, Bedford Park, South Australia, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Frazer Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Centre for Cancer Biology, and Clinical Health Sciences, University of South Australia, Adelaide, South Australia, Australia, ⁷Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Rheumatoid arthritis (RA) shows heterogeneous therapeutic responses that may reflect diversity within synovial tissue (ST). We aimed to identify gene signatures that predict Adalimumab…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].